Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
  • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Definitions

• the present invention relates to a functional material containing a useful phospholipid composition and a functional food to which the functional material is added. More specifically, a functional material containing a useful phospholipid composition and a functional substance as active ingredients, a functional material containing a functional substance in a ribosome formed by the useful phospholipid composition, and the functional material Relates to functional foods.
• a functional material containing a useful phospholipid composition and a functional substance as active ingredients More specifically, a functional material containing a useful phospholipid composition and a functional substance as active ingredients, a functional material containing a functional substance in a ribosome formed by the useful phospholipid composition, and the functional material Relates to functional foods.
• Patent Document 1 Non-Patent Document 1
• EPA eicosapentaenoic acid
• DHA docosahexaenoic acid
• lipophilic components are poorly soluble in powerful human body fluids such as water and blood, so the absorption efficiency into the human body is low. There are cases where expensive and valuable materials are always wasted.
• Various formulation technologies for improving the absorption efficiency of these lipophilic components and hydrophilic components have been proposed and have become important elemental technologies in the food and pharmaceutical fields.
• Patent Document 1 Japanese Patent Application Laid-Open No. 11 123052
• Patent Document 2 JP 2002-272493 A
• Non-Patent Document 1 Yoshie Inoue, Food and Development, 31, 1, p. 49
• Non-Patent Document 2 Agaritas Internet ⁇ URL: HYPERLINK "http://www.aicplus.com/about http://www.aicplus.com/about agaricus / index, html, August 19, 2005 Search
• Non-Patent Document 3 Japan Coenzyme Q Association Internet URL: HYPERLINK "http: / / www. Coenzymeq-jp.com/ enterprise. Html # qlO ⁇ http: //www.coenzymeq—jp.com/ ente rprise.html # qlO, searched on August 19, 2005
• Non-Patent Document 4 Fragrance Journal, No. 15, p. 68-76, 1965
• the present invention includes a useful phospholipid composition in which a useful phospholipid and a functional substance are used as active ingredients, and the physiological function is effectively utilized to improve physiological activity.
• the present inventors have conducted intensive research and combined useful phospholipids and functional substances in combination, or useful phospholipids containing functional substances in ribosomes of useful phospholipids. It has been found that the functional material containing the composition can enhance its physiological function as compared with the case where the functional substance is administered alone, and the present invention has been completed.
• the functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance as active ingredients. It is characterized by that.
• the functional material containing the useful phospholipid composition of the present invention is omega-3 highly unsaturated. It consists of a ribosome comprising a useful phospholipid composition containing a fatty acid-binding phospholipid and a functional substance, wherein the functional substance is encapsulated in the ribosome.
• the omega-3 polyunsaturated fatty acid-binding phospholipid is composed of 10% by weight or more, preferably 20% by weight or more, of DHA (docosahexaenoic acid) and Z Or EPA (eicosapentaenoic acid).
• the omega-3 polyunsaturated fatty acid-binding phospholipid is preferably a useful phospholipid composition in which the content of omega-3 polyunsaturated fatty acid is increased by transesterification.
• the functional substance is preferably a functional food material or a pharmaceutical material.
• the functional substance is preferably agaritas or coenzyme Q10.
• the omega-3 polyunsaturated fatty acid-binding phospholipid is preferably derived from aquatic products, and the aquatic organism is preferably any of fish eggs, aquatic animal gonads, squid, scallops, starfish, seaweeds and microorganisms. .
• the useful phospholipid is a naturally-derived omega-3 polyunsaturated fatty acid-binding phospholipid, and contains a food material or a pharmaceutical material as a functional substance, or these It is possible to provide a functional material containing a useful phospholipid composition encapsulating the functional substance.
• the functional substance is agaritas or coenzyme Q10
• the effect is significantly higher than that of any single unit of omega-3 highly unsaturated fatty acid-binding phospholipid or agaritas. .
• the functional food of the present invention preferably contains a functional material containing the useful phospholipid composition.
• the functional food may be a solid food or a beverage.
• useful phospholipid compositions and functional substances are contained or useful It is possible to provide a functional material that can encapsulate a functional substance in a ribosome having a lipid composition and improve its bioavailability and a food containing the functional material. In particular, when taken as a beverage, the absorption efficiency of functional substances in the body can be improved.
• FIG. 1 is a diagram schematically showing the structure of another functional material of the present invention.
• FIG. 2 is a view showing the size of cancer cells inoculated in mice when water containing the compositions of Example 1 and Comparative Examples 1 and 2 was freely ingested.
• FIG. 3 is a graph showing the weight% of cancer cells on the 21st day relative to the body weight in Example 1 and Comparative Examples 1 and 2.
• FIG. 4 is a graph showing the weight of cancer cells inoculated in mice when water containing the compositions of Example 2 and Comparative Examples 1 and 2 was freely ingested.
• the functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition and a functional substance as active ingredients.
• the phospholipid is, for example, a glycerin phosphate ester represented by the chemical formula (1), including seafood, egg yolk, soybeans, and the like. It is contained in a lot and is used for extraction.
• an alcoholamine group whose force is selected from (PE), inositol (PI), serine (PS), and glycerol (PG).
• the group X may be a group in which a polyhydric alcohol is ester-bonded.
• glycerin phosphates examples include phosphatidylcholine represented by chemical formula (2) and phosphatidylserine represented by chemical formula (3).
• R COO and R COO are fatty acid residues and are represented by the chemical formula (1)
• the acid ester X is choline (PC) or serine (PS).
• PC choline
• PS serine
• omega (taenoic acid) group is shown in the following formulas (4) and (5).
• DHA and EPA are both called omega ( ⁇ ) -3 highly unsaturated fatty acids because the carbon located third from the end has an unsaturated bond.
• Phospholipids containing unsaturated fatty acids are omega-3 highly unsaturated fatty acid-bound phospholipids.
• omega-3 polyunsaturated fatty acid-binding phospholipids are called useful phospholipids, or omega-3 phospholipids are called ⁇ -3 phospholipids.
• Useful phospholipids have a structure having a good balance between a phosphate group as a hydrophilic group and an alkyl group and an alkenyl group as a lipophilic group. It exhibits the property of forming ribosomes, which are emulsified fine particles in human cells, and taking in the lyophilic and lipophilic components therein.
• the chemical substance that forms an ester bond to the phosphate part of the useful phospholipid is a phospholipid phosphatidylserine that is a phospholipid bound to phosphatidylcholine that is a main component of phosphatidylcholine, which is a choline.
• a positive charge to the surface it is possible to repel each other electrically in the liquid and to significantly increase the stability of the ribosome in the dispersion.
• the coexistence concentration is 5% by weight or more and the stability is remarkable, and 60% by weight or less is preferable.
• fatty acids that are ester-bonded in useful phospholipids include DHA, which is an omega-3 highly unsaturated fatty acid, and ⁇ or ⁇ .
• DHA which is an omega-3 highly unsaturated fatty acid
• ⁇ or ⁇ an omega-3 highly unsaturated fatty acid
• the effect of the present invention can be obtained if omega-3 highly unsaturated fatty acid is contained even in a small amount. The higher the concentration, the more effective. Specifically, a clear effect is exhibited at 10% by weight or more of the fatty acid ester-bonded in the useful phospholipid, and 20% by weight or more is particularly desirable.
• phosphatidylserine may be produced by extracting phospholipids derived from aquatic products, or by converting phospholipids such as phosphatidylcholine by phosphatidyl group transfer reaction in the presence of L-serine (Patent Literature). 2). Further, it may be extracted by transesterification by an enzymatic method or the like. Furthermore, by adding cholesterol appropriately in the range of 1% by weight to 50% by weight, the strength of the ribosome membrane can be increased and the dispersion stability can be improved.
• the functional substance 2 can be any functional food material or pharmaceutical material!
• Such functional food materials include mushroom extract such as Agaritas, Meshimakobu, Hanabiratake, Coenzyme Q10, water-soluble peptide, carotenoids such as carotene, polyphenol, tea catechin, yew leaf extract, various herbs, Flavonoids such as isoflavones, folic acid, vitamins, minerals, amino acids, tocopherol, dalcosamine, hyaluronic acid, chondroitin sulfate, collagen, fucoidan, chitin, chitosan, blueberry, lutein, austaxanthin, etc., DHA, EPA, etc.
• Coenzyme Q10 is a substance that is also produced in human cells and is called the “genuine element” of the human body, and many products are sold as supplements for health, beauty and physical fitness.
• the phospholipid useful for the human body Due to the synergistic effect of the physiologically active function of the composition and the functional substance, a functional food having an extremely high physiologically active function can be provided. In particular, when the functional substance is agaritas, the effect can express a higher bioactive function than either the phospholipid composition or the functional substance alone.
• FIG. 1 schematically shows the structure of a functional material containing another useful phospholipid composition of the present invention.
• the functional material containing the useful phospholipid composition of the present invention contains functional substance 3 composed of active ingredients of functional food material and pharmaceutical material in ribosome 2 composed of useful phospholipid 1.
• Ribosome 2 which contains a functional substance, forms fine particles by emulsifying and aggregating useful phospholipids in water.
• the particle size of ribosome 2 varies depending on the liposome formation conditions, and is usually 10 m or less, more preferably 1 ⁇ m or less.
• useful phospholipids and functional substances the same materials as the above functional materials can be suitably used.
• useful phospholipids may be modified or derivatives of phospholipids to which omega binds and have a liposomal effect.
• Such lipids may be glycolipids such as digalatatosyldiacylglycerol (DGDG)! /.
• DGDG digalatatosyldiacylglycerol
• the functional material 1 containing the useful phospholipid composition of the present invention is also referred to as a ribosome preparation 1 containing the functional substance 3 or a ribosome preparation 1 as appropriate.
• the ribosome is a closed vesicle that forms a bilayer membrane composed of useful phospholipids and has an aqueous phase therein.
• emulsification which is a system in which one of the two liquids, such as water and oil, that do not mix is finely divided and dispersed in the other phase.
• the emulsion is stabilized using a surfactant or the like.
• useful phospholipid itself also has a surfactant action, in the present invention, it is used as a bilayer membrane of ribosome.
• ribosomes are multilamellar ribosomes (0.1 ⁇ m to several ⁇ m) and single membrane ribosomes (0.01 ⁇ m to number / zm).
• the former includes multi-layer ribosomes (MLV), multilamellar ribosomes (OLV), and multiphase ribosomes, and the latter includes small single-membrane ribosomes (SUVs) and large single ribosomes.
• MLV multi-layer ribosomes
• OSV multilamellar ribosomes
• SVS small single-membrane ribosomes
• SAVs small single-membrane ribosomes
• the mass production method may be a polyhydric alcohol method, a heating method, a spray drying method, a mechanochemical method, or the like.
• the functional material containing the useful phospholipid composition of the present invention can be produced by encapsulating the functional substance 3 in the ribosome when forming a ribosome having a useful phospholipid power.
• the functional substance is added in an amount of 1 to 90% by weight, preferably 20 to 70% by weight, inside the ribosome.
• the ribosome 2 is formed with the useful phospholipid, and the functional substance 3 is encapsulated therein.
• the functional material 1 that also has a ribosome power of a useful phospholipid encapsulating a functional substance that improves various bioavailability. Therefore, when used as a functional material containing the useful phospholipid composition of the present invention, it is possible to exert more physical functions than the administration of the functional substance alone.
• useful phospholipids are known to have many physiological activities, and are also good surfactants. Therefore, a functional material in which useful phospholipids themselves are ribosomed and a functional material is encapsulated therein can be dispersed without using other special additives such as surfactants. For this reason, ribosome 2 can be efficiently formed by adding a useful phospholipid to water and applying a treatment to form a lipid bilayer membrane of phospholipid.
• useful phospholipids have physiological activities such as liver function improvement, blood pressure lowering, anti-allergy, memory function improvement such as memory ability, and anti-cancer. Synergistic effects with physiologically active ingredients in lipids can also improve the overall physiological function.
• a ribosome preparation containing the functional substance can be prepared by emulsifying a mixture of the useful phospholipid composition and the predetermined functional substance in water. This emulsification can be carried out by vigorously stirring water, the useful phospholipid composition and the functional substance, or by spraying them through micropores.
• the functional substance is hydrophilic, the functional substance is easily taken up into the phospholipid bilayer membrane of the ribosome and becomes a uniform emulsion (see Fig. 1).
• the functional substance is lipophilic, a part or all of the functional substance is sandwiched between layers of the phospholipid bilayer inside the liposome, and held or encapsulated inside the phospholipid.
• the particle size of ribosome formed by emulsification is 10 / z m or less.
• the particle size distribution can be appropriately adjusted.
• the particle size and particle size distribution should be designed appropriately according to the application.
• Useful phospholipids include fish eggs such as salmon roe, demolition power such as bonito and tuna, gonads, squid, starfish, and oils derived from aquatic products such as scallops, starfish, seaweed and microorganisms. Extracted and purified omega-3 polyunsaturated fatty acid binding phospholipids can be used.
• the functional material containing the useful phospholipid composition in which the useful phospholipid itself of the present invention is ribosomed and the functional material is encapsulated inside or between the phospholipid bilayer membranes. can be manufactured efficiently.
• Example 1 a functional material containing a useful phospholipid composition containing a useful phospholipid composition and a functional substance as active ingredients was produced. Specifically, omega-3 highly unsaturated fatty acid-binding phospholipid derived from squid meal dissolved in hexane is placed in an eggplant-shaped flask so that the phospholipid forms a thin film on its side wall under a nitrogen gas stream. Then, the mixture was allowed to dry and then left under reduced pressure to completely distill off the solvent to obtain a dried product. 0.4 g of this dried product was dispersed in 10 OOcm 3 of pure water. On the other hand, lgaritas (manufactured by Health Science Co., Ltd., AICPLUS) water extract lyophilized powder 1 g was dissolved in 1000 cm 3 of pure water.
• omega-3 highly unsaturated fatty acid-binding phospholipid derived from squid meal dissolved in hexane is placed in an eggplant-shaped flask so that the phospholipid forms
• Example 1 the functional dispersion of Example 1 was prepared by mixing equal amounts of the above aqueous solution of dried solids and an aqueous solution of agaritas.
• Example 2 a squid liposome-derived phospholipid is used as a raw material for ribosome 2, and Agaritas (AICPLUS, manufactured by Health Science Co., Ltd.) is used as functional substance 3, and a ribosome preparation containing a functional substance 1 was prepared.
• AICPLUS Agaritas
• Agarix was encapsulated in ribosomes from squid omega-3 highly unsaturated fatty acid-binding phospholipids by the following procedure.
• ribosome preparation 1 containing fragritas of Example 2 was prepared.
• ribosomal formulation 1 containing the Agari task of Example 2 the emulsion lcm 3 per DHA (omega one 3) the phospholipid content is 0. 2 mg / cm 3, Agaritasu content per emulsion lcm 3 The amount was 0.5 mg.
• PS phosphatidylserine
• cholesterol may be appropriately added during the preparation of the dried product.
• Omega 3 highly unsaturated fatty acid-binding phospholipid derived from squid of Comparative Example 1 was prepared in the same manner as in Example 2 except that no agaritas was added.
• the content of omega-3 highly unsaturated fatty acid-bound phospholipid containing DHA as the main component per lcm 3 of the emulsion is 0.2 mg / cm 3 .
• composition was mixed with water and allowed to freely ingest as a beverage in mice (BALBZc), and the effect on cancer cells (SP2tumors) inoculated into the mice was examined.
• the beverage was given daily from day 7 onwards after cancer cell inoculation.
• Example 1 Comparative Examples 1 and 2
• FIG. 2 shows the size of cancer cells inoculated in mice when water containing the compositions of Example 1 and Comparative Examples 1 and 2 was freely ingested.
• the horizontal axis represents the number of days after cancer cell inoculation, and the vertical axis represents the size (mm 3 ) of cancer cells.
• the figure also shows the data of mice that freely ingested water that did not contain any of the above-mentioned compositions for comparison with Example 1 and Comparative Examples 1 and 2 (Fig. 1). See no treatment).
• Example 1 As apparent from FIG. 2, the cancer cells of 21 day, Example 1, Comparative Example 1, Comparative Example 2, the case of no administration, respectively, 2mm 3, 4mm 3, 3. 5mm 3, 7mm 3 Thus, in the case of Example 1, only about 30% proliferated compared with the case of no administration. From this, in the case of Example 1, the effect of suppressing the proliferation of cancer cells was remarkably recognized.
• FIG. 3 shows the weight of the cancer cells on the 21st day relative to the body weight in Example 1 and Comparative Examples 1 and 2. It is the figure which showed quantity%.
• the vertical axis represents the weight% of cancer cells.
• the weight percentage of cancer cells is 8% (about 24% without administration), 20%, 17% in Examples Comparative Example 1, Comparative Example 2 and no administration, respectively.
• the weight percentage of cancer cells was about 24% without administration, and the effect of suppressing the growth of cancer cells was remarkably observed. .
• FIG. 4 is a graph showing the weight of cancer cells inoculated into mice when water containing the compositions of Example 2 and Comparative Examples 1 and 2 was freely ingested.
• the horizontal axis indicates the number of days after cancer cell inoculation, and the vertical axis indicates the weight (g) of cancer cells.
• the figure also shows the data of a mouse that freely ingested water without any of the above-mentioned composition for comparison with Example 2 and Comparative Examples 1 and 2 (FIG. 4). No administration).
• mice that freely ingested water containing ribosome formulation 1 containing fragritas in Example 2 showed a gradual growth of cancer cells on the 19th day. 27 g of eyes were alive.
• mice that were given free access to water containing DHA (omega 3) phospholipid ribosome derived from squid in Comparative Example 1 showed growth of cancer cells on day 12 and died on day 19, The weight of the cancer cell at that time was 30 g.
• mice that were freely ingested with water containing agaritas of Comparative Example 2 showed gradually growing cancer cells from day 13 and reached 40 g on day 35, but survived.
• Example 2 and Comparative Example the growth of cancer cells was slowed in the order of Comparative Example 2 and Example 2 in comparison with no administration and Comparative Example 1 that died on the 19th day.
• the cancer cell growth inhibitory effect was observed.
• the cancer cell growth inhibitory effect is further enhanced than the case of the administration of agaritas alone of Comparative Example 2. Admitted.
• the growth of cancer cells was slower in the case of the thread and adult product that only the DHA (omega-3) -bound phospholipid ribosome derived from squid in Comparative Example 1 was used. I helped.
• Example 3 a ribosome preparation 1 containing a functional substance was prepared in the same manner as in Example 2, except that Coenzyme Q10 (manufactured by Nisshin Faluma) was used as the functional substance 3. A total of 25 mg of a drink (100 cm 3 ) in which the functional material of Example 3 was dispersed was given to 3 healthy males.
• Coenzyme Q10 manufactured by Nisshin Faluma
• the functional material 1 containing the useful phospholipid of Example 4 was prepared in the same manner as in Example 2 except that the scallop-derived phospholipid described later was used.
• the scallop-derived phospholipid was prepared as follows.
• a useful phospholipid composition of Example 4 was produced using scallop as a starting material.
• the starting material has a scallop mouth weight of 1000kg, which has been drained for a while but not particularly dry (hereinafter referred to as the wet standard).
• the breakdown is 23% by weight solids and water strength S770kg.
• the protein in this solid content is about 13.5% in the case of scallop mouth.
• the starting materials were continuously added, and the first steaming process and the second solid-liquid separation process were continuously performed. Specifically, 2000 liters of water is added to starting material 1 and steam jar is added. It was heated and boiled at a temperature of 95-100 ° C and a residence time of 20 minutes in a continuous heating tube.
• the extract obtained here was a brown sticky liquid, and its weight was 15.5 kg.
• the extract was passed through a stainless steel cup-top column having a diameter of 50 cm and a height of 1.5 m.
• the chromatographic column is packed with silica gel.
• Silica gel Hishigel, manufactured by Dokai Chemical Co., Ltd.
• Separation was developed with 95 wt% ethanol.
• the dark black-brown initial fraction was separated and discarded, and then the effluent phase that became light brown was collected as the target fraction.
• ethanol was distilled off from the purified solution under the same conditions as in the fourth step to obtain 7.8 kg of an oil phase as a useful phospholipid composition.
• This useful phospholipid composition had a black-brown appearance and an oily appearance.
• Example 4 In the same manner as in Examples 1 and 2, a drinking water addition test to mice was performed. As a result, the amount of cancer cells on day 19 was 1.2 g, 30 g, 4 g, and 39 g in Example 4, Comparative Example 1, Comparative Example 2, and no administration, respectively. In the case of Example 4, the amount of cancer cells was as small as 3% with no administration, showing a very high cancer cell suppression effect.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Dispersion Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Non-Alcoholic Beverages (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37962479

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (3)

Citations (2)

• 2005
  • 2005-10-17 JP JP2005302339A patent/JP2007110904A/ja active Pending
• 2006
  • 2006-10-17 WO PCT/JP2006/320670 patent/WO2007046386A1/ja not_active Ceased

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events